Repligen (RGEN) Downgraded to Sell at BidaskClub

Repligen (NASDAQ:RGEN) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday.

Other equities analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. Citigroup assumed coverage on shares of Repligen in a research report on Friday, December 8th. They set a “buy” rating and a $45.00 price objective for the company. First Analysis upgraded shares of Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 price target for the company in a research report on Monday, October 2nd. CL King assumed coverage on shares of Repligen in a research report on Monday, November 13th. They issued a “buy” rating and a $41.00 price target for the company. Finally, Jefferies Group restated a “hold” rating and issued a $40.00 price target on shares of Repligen in a research report on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $44.38.

Repligen (NASDAQ RGEN) traded up $0.90 during mid-day trading on Friday, reaching $35.78. 189,627 shares of the company were exchanged, compared to its average volume of 180,021. The firm has a market cap of $1,558.76, a PE ratio of 60.64, a price-to-earnings-growth ratio of 2.01 and a beta of 1.04. Repligen has a twelve month low of $28.48 and a twelve month high of $46.81.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.04. The business had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The firm’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.08 EPS. equities research analysts anticipate that Repligen will post 0.61 EPS for the current fiscal year.

In other Repligen news, VP Howard Benjamin sold 12,729 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $35.34, for a total value of $449,842.86. Following the completion of the transaction, the vice president now directly owns 36,554 shares in the company, valued at approximately $1,291,818.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Large investors have recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in shares of Repligen in the 2nd quarter valued at $120,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Repligen in the 2nd quarter valued at $123,000. Victory Capital Management Inc. boosted its stake in shares of Repligen by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 4,001 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 601 shares during the last quarter. Pinebridge Investments L.P. boosted its stake in shares of Repligen by 1.7% in the 2nd quarter. Pinebridge Investments L.P. now owns 4,491 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 76 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Repligen in the 3rd quarter valued at $180,000. 83.21% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/21/repligen-rgen-downgraded-to-sell-at-bidaskclub.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply